India Cardiovascular Diseases Therapeutics Market Report 2022 to 2030

India Cardiovascular Diseases Therapeutics Market Analysis

$ 3999

India's cardiovascular disease therapeutics market is projected to grow from $2.95 Bn in 2022 to $6.44 Bn in 2030 with a CAGR of 10.22% for the year 2022-2030. The changing lifestyles leading to the increased prevalence of hypertension and other cardiovascular diseases are the major market drivers. The India cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Aventis Pharma, Viridis Biopharma, and Bayer are the major players in the India cardiovascular disease therapeutics market.

ID: IN10INPH033 CATEGORY: Pharmaceuticals GEOGRAPHY: India AUTHOR: Parul Choudhary

Buy Now

India Cardiovascular Disease Therapeutics Market Executive Analysis

India's cardiovascular disease therapeutics market is projected to grow from $2.95 Bn in 2022 to $6.44 Bn in 2030 with a CAGR of 10.22% for the year 2022-30. The Ministry of Health and Family Welfare received a budget of $1.04 Bn for 2022-23. Comparing the current allocation to the prior fiscal year's allocation, a small increase has occurred. The National Health Policy (NHP), published in 2017, states that by 2025, health expenditure should equal 2.5% of the GDP. The National Health Mission's (NHM) budget allotment has largely remained constant, rising just 0.8% to $352 Mn in 2023-24 from $350 Mn in 2022-23.

The Indian pharmaceutical market is currently ranked third in the world in terms of volume. Furthermore, India continues to be one of the most alluring locations in the world for clinical trials, despite recent regulatory changes brought on by issues primarily related to ethics, accountability, and pay.

One of the greatest global burdens of cardiovascular disease (CVD) is found in India. According to projections, there will be 4.77 Mn CVD-related fatalities annually in India by 2020, up from 2.26 Mn in 1990. Over the past several decades, estimates of the prevalence of coronary heart disease in India's population have varied from 1.6% to 7.4% in rural areas and from 1% to 13.2% in urban areas.

india cardiovascular disease therapeutics market

Market Dynamics

Market Growth Drivers

The incidence of cardiovascular diseases has significantly increased in India in recent years, mainly as a result of altered lifestyle habits like unhealthy eating habits, inactivity, and smoking. The need for therapeutics for cardiovascular disease has increased as a consequence of this. India is becoming more and more conscious of the value of preventing cardiovascular diseases through dietary changes and early diagnosis. The use of therapeutics to control and treat cardiovascular diseases has become more important as a result of this, increasing the emphasis on preventive healthcare. Statins, ACE inhibitors, and beta blockers are a few examples of advanced therapeutics for cardiovascular illnesses that have been created as a result of advancements in medical technology. These developments have raised the demand for the India cardiovascular disease therapeutics market.

Market Restraints

Cardiovascular disease treatment can be quite expensive, particularly for people who need long-term medication and hospitalization. There are still many areas of India with insufficient access to medical institutions, skilled healthcare workers, and cutting-edge diagnostic and therapeutic technologies. This may make it more difficult for patients to get access to high-quality treatment for cardiovascular conditions. Many patients in India do not have sufficient health insurance, which may restrict their access to expensive therapies and treatments for cardiovascular disease thereby limiting the growth of the India cardiovascular disease therapeutics market

Competitive Landscape

Key Players

Sun Pharmaceuticals (IND)
Torrent Pharmaceuticals (IND)
Oceanic Pharmachem (IND)
Aventis Pharma (IND)
Viridis Biopharma (IND)
Bayer
Janssen Pharmaceuticals
AstraZeneca
Sanofi
Novartis
Merck
Gilead Sciences

Healthcare Policies and Regulatory Landscape

The Ayushman Bharat scheme is one of many public healthcare initiatives launched by the Indian government with the goal of providing low-income households with access to healthcare. These plans offer coverage for interventions like angioplasty and bypass surgery as part of CVD treatment. The level of care can differ greatly and the coverage may be limited. For some medical operations, such as CVD-related treatments like angioplasty and bypass surgery, the Indian government has established reimbursement policies. The reimbursement rates, however, might not fully cover the expense of care, leaving patients with a heavy financial burden.

In India, treating CVD with medications like statins, beta-blockers, and ACE inhibitors is a usual practice. The use of more recent medications, like PCSK9 inhibitors, which have been demonstrated to be more efficient at lowering LDL cholesterol levels, is on the rise. In India, interventional techniques like angioplasty and bypass surgery are frequently used to address CVD. Minimally invasive treatments, like TAVR and TMVR, which are less invasive and require less recovery time, are becoming more and more popular. In India, the management of CVD is increasingly being done using telemedicine and remote surveillance. By delivering timely and individualized treatment, these technologies can aid in improving patient outcomes.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

India Cardiovascular Disease Therapeutics Segmentation

By Disease Indication (Revenue, USD Billion):

Hypertension
Coronary Artery Disease
Hyperlipidaemia
Arrhythmia
Others

By Drug Type (Revenue, USD Billion):

Antihypertensive
Anticoagulants
Antihyperlipidemic
Antiplatelet Drugs
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Drug Classification (Revenue, USD Billion):

Branded Drugs
Generic Drugs

By Mode of Purchase (Revenue, USD Billion):

Prescription-Based Drugs
Over-The-Counter Drugs

By End Users (Revenue, USD Billion):

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.